Interview with Aimee Near, Principal of IQVIA’s USA Medical and Scientific Services: RWE in Pharma

IQVIA’s Aimee Near took part in The Evidence Base’s RWE in Pharma interview series. In her interview, Near talks about her role at IQVIA and the recent shift in how the pharmaceutical industry uses real-world data (RWD). In addition, she explains how to find useful data sets by performing a data landscape assessment. After touching on patient groups’ and physicians’ growing interest in RWD, Near gives her 5-year outlook on RWD and RWE in pharma.

According to Near, “Overall, I think we’ll see an increased use of RWD to support regulatory decision making. We have seen off-label use in RWD which has supported label expansions and leveraging of RWD for external control arms. RWD is also evolving to include more novel data, such as data generated from wearables, as well as genomic data, which I am personally very excited about for the future of targeted therapy regulatory decisions. I think pharma’s use of RWD will continue to grow and be apparent in supporting more and more regulatory approvals.”

Read the entire interview by clicking here.

(Source: The Evidence Base, December 3^rd, 2021)